Background
==========

Neuroblastoma is a childhood malignancy that arises from embryonic cells of the sympathetic ganglia or the adrenal medulla \[[@B1]\]. It is mainly a disease of infants and toddlers; more than half of patients with neuroblastoma are diagnosed before two years of age and \~90 percent before age six \[[@B2],[@B3]\]. This age dependence of the incidence of neuroblastoma may be a consequence of developmentally determined disappearance of the pool of immature cells from which neuroblastomas are thought to derive. The disease is clinically diverse, and ranges from cases with a very dismal prognosis, despite modern intensive multimodal therapy, to those with an excellent chance of survival \[[@B2]\]. This variation in clinical behavior is also highly age dependent: children who are diagnosed after two years of age suffer predominantly from aggressive forms. Neuroblastomas that are diagnosed during adolescence and young adulthood are rare, but they are of particular concern because they almost invariably progress, although with an indolent course \[[@B4],[@B5]\]. In sharp contrast, tumors that are diagnosed before 18 months of age are generally associated with a favorable prognosis. Such tumors are usually less advanced, have a propensity for spontaneous involution or maturation, and respond well to mild chemotherapy \[[@B2]\].

These clinical differences correspond to clear differences in tumor genetics \[[@B2]\]. As a general rule, prognostically favorable tumors display numerical imbalances of entire chromosomes and have near-triploid DNA content, whereas higher-risk tumors present with segmental chromosomal aberrations (SCAs) and are often pseudo-diploid. *MYCN* gene amplification (MNA) was one of the first genetic markers for highly aggressive neuroblastoma to be established \[[@B6]\], and remains a powerful prognostic indicator \[[@B7]\]. More recently, an independent prognostic value of a segmental deletion of 11q has also been recognized \[[@B7]-[@B9]\]. Both these aberrations are incorporated in the present International Neuroblastoma Risk Group (INRG) classification system for treatment stratification \[[@B10]\]. Several arrayCGH studies in the recent years support the MNA/segmental 11q loss dichotomy of high-risk neuroblastoma and indicate that any type of segmental numerical chromosomal aberration is a negative prognostic sign \[[@B11]-[@B13]\]. However, the representativeness of the studied tumor materials may be questioned because the tumors were from multiple sources and, hence, selection bias may have occurred. Therefore, the present study aims at characterizing the heterogeneity of genetic aberrations in aggressive neuroblastoma by exploiting a consecutive, population-based series of tumors, the representativeness of which was tested against data in the Swedish Childhood Cancer Registry. The most striking observations were related to age at tumor presentation: MNA tumors were associated with a particularly early age at diagnosis and low numbers of other chromosomal aberrations suggesting a rapid tumor evolution with few genetic hits involved, whereas 11q deleted tumors were diagnosed at older ages and showed significantly more SCAs, the numbers of which were positively correlated with the age at diagnosis, suggesting a chromosomal instability phenotype with a more stepwise tumor evolution. Other tumors seemed to be the result of late progression of low-risk neuroblastoma or of gene amplifications other than *MYCN*. This clinicogenetic diversity of unfavorable neuroblastoma is likely to reflect differences in tumor evolution and growth, which may have therapeutic implications.

Methods
=======

Study design
------------

In order to obtain a representative view at high resolution of DNA copy number aberrations in aggressive forms of neuroblastoma a 32K BAC whole-genome tiling path arrayCGH platform was applied to a consecutive, population-based tumor material (described below). The representativeness of the tumor collection was analyzed by comparing the patients' ages at diagnosis and proportions of tumors in relation to the presence or absence of MNA with the corresponding data of neuroblastomas registered in the Swedish Childhood Cancer Registry during a 25-year period. For verification of the BACarray-based profiles high-resolution SNP array analyses were performed. Based on publically available gene expression data from neuroblastoma, expression profiles were compared between tumor groups for certain chromosomal regions of interest.

Patient material
----------------

Fresh frozen specimens of neuroblastoma were collected consecutively during the period 1986--1994 at all Swedish centers at which pediatric tumor surgery is performed \[[@B14]\]. Samples collected between 1995 and 2010 at Uppsala University Hospital, which treats approximately 20 percent of Swedish patients with neuroblastoma, were also included. The inclusion criteria were: high-risk neuroblastoma, as defined by the INRG classification system \[[@B10]\], progression to disseminated fatal disease, and stage L2 tumors in children \>12 years of age at diagnosis (one case). The INRG high-risk criteria applied here were: Stage M tumors in children \>18 months of age at diagnosis and all tumors with MNA. Stage MS tumors were excluded. The individual clinical data of all 34 cases included in the study are shown in Table [1](#T1){ref-type="table"}.

###### 

Clinical data and main genetic findings of 34 unfavorable neuroblastomas

          **ID**          **Age**   **Sex**   **Stage**   **Outcome**   **Followup**   **Survival median**   **Site**   **WCA**   **WCA**   **SCA**   **SCA**    **MNA**   **11q-**   **Array platform**
  ---------------------- --------- --------- ----------- ------------- -------------- --------------------- ---------- --------- --------- --------- ---------- --------- ---------- --------------------
           52\*              4         m          M           DOD            10                                adr         0                   6                   \+                        32K
            55               8         f          M           DOD            16                                adr         0                   6                   \+                  32K, Affymetrix
          106\*             10         f          M           NED           265                                adr         0                  12                   \+                        32K
          123\*             11         f          M           DOD            3                                 adr         0                   6                   \+                  32K, Affymetrix
          241\*             11         m          M           DOD            8                                 adr         1                   3                   \+                  32K, Affymetrix
           244              14         f          M           DOD            22                                adr         8                   2                   \+                     Affymetrix
           212              15         m          M           DOD            5                                 adr         0                   2                   \+                  32K, Affymetrix
          240\*             21         f          M           NED            43                                adr         0                   3                   \+                  32K, Affymetrix
          135\*             22         m         L2           DOD            3                                 adr         0                   3                   \+                  32K, Affymetrix
           95\*             26         f          M           DOD            15                                adr         0                   8                   \+                        32K
           238              30         f          M           DOD            24                                adr         0                   6                   \+                     Affymetrix
           207              37         f          M           DOD            7                                 adr         2                   5                   \+                  32K, Affymetrix
           217              37         m          M           DOD            36                                adr         0                   8                   \+                        32K
           126              138        m          M           DOD            9                                 adr         0                   7                   \+                  32K, Affymetrix
   **MNA**^**not11q-**^                                                                      **9.5**                              **0.8**             **5.5**                                  
            68              41         m          M           DOD            12                                adr         9                   7                   \+         \+       32K, Affymetrix
          136\*             48         f         L2           DOD            12                                adr         1                   8                   \+         \+             32K
    **MNA** &**11q-**                                                                       **12.0**                              **5.0**             **7.5**                                  
           243              32         f          M           DOD            28                                adr         2                  10                              \+          Affymetrix
           149              34         m          M           DOD            16                                adr         0                  12                              \+       32K, Affymetrix
           112              40         m          M           DOD            18                                adr         1                   3                              \+       32K, Affymetrix
          111\*             42         f          M           NED           262                                adr         0                   7                              \+             32K
           155              52         f          M           DOD            19                                adr         3                  13                              \+       32K, Affymetrix
           32\*             57         m          M           DOD            12                                adr         2                  15                              \+       32K, Affymetrix
           110              60         m          M           DOD            12                                adr         1                  14                              \+       32K, Affymetrix
           69\*             60         m         L2           DOD            17                                 th         1                  14                              \+       32K, Affymetrix
           41\*             77         f          M           DOD            8                                  th         2                  15                              \+       32K, Affymetrix
            49              82         m          M           DOD            14                                adr         3                  10                              \+       32K, Affymetrix
           209              129        m          M           DOD            35                                adr         2                  10                              \+       32K, Affymetrix
           229              169        m         L2           DOD            34                                adr         1                  21                              \+       32K, Affymetrix
   **11q-**^**notMNA**^                                                                     **16.5**                              **1.5**             **12.0**                                 
          107\*             23         m          M           DOD            10                                adr         1                   2                                       32K, Affymetriix
           131              37         f         L2           DOD            21                                adr        13                   1                                       32K, Affymetriix
           130              46         m          M           DOD            57                                adr         0                   3                                       32K, Affymetriix
           208              59         m         L2           DOD            25                               renal        4                   3                                             32K
          242\*             90         f          M           SD             37                                 th        12                   5                                       32K, Affymetriix
          226\*             91         m          M           SD             61                                 th         2                  12                                       32K, Affymetriix
   **Not MNA not 11q-**                                                                     **23.0**                              **5.3**             **4.3**                                  

Cases are sorted on the basis of genetic category, as determined by the presence of MNA and segmental loss of 11q. Within each tumor category, cases are sorted according to age at diagnosis. Abbreviations: DOD: dead of disease; NED: no evidence of disease; SD: stable disease; WCA: whole-chromosome copy number aberration; SCA: segmental chromosomal copy number aberration; adr: adrenal; th: thoracic. Tumors marked with asterisk (\*) with IDs: 52, 106, 123, 241, 240, 135, 95, 136, 111, 32, 69, 41, 107, 242, and 226 are reported also by Carén et al. \[[@B15]\] with the respective codes: 7, 14, 8, 2, 4, 13, 12, 37, 40, 42, 44, 39, 66, 73, and 63, as listed in \[15; Table S1\].

To ensure that the tumor specimens represented viable tumor tissue their quality was assessed from hematoxylin/eosin stained cryosections, requiring a tumor cell content of at least 60--70%. Ethical approval was obtained from the Regional Ethical Review Board in Uppsala (approval 2007/069), and written informed consent was obtained from the parents.

There is an overlap between tumors included in this work and those of a similar Swedish report \[[@B15]\]. However, our study is based on another collection of biopsies from a partially different set of tumors. The previously reported Affymetrix SNParray data \[[@B15]\] was used for verification of our BACarray results on tumors common to both studies (n=15) and for verification of our data on presently unique tumors (n=19) new original SNParray data was produced. Tumors in common with the aforementioned study are indicated in Table [1](#T1){ref-type="table"} and information on their previous codes \[15; Table S1\] is given in the table legend.

Array-based comparative genomic hybridization
---------------------------------------------

The 32K BAC array was established as reported previously \[[@B16]\]. High-quality DNA was obtained by standard methods \[[@B17]\]. DNA labeling, hybridization, washing, scanning of arrays, and data processing were performed as described earlier \[[@B16],[@B18]-[@B20]\]. Experiments using 50K and 250K Affymetrix arrays were performed in accordance with the manufacturer's protocol (Affymetrix, Inc., Santa Clara, CA), and as described earlier \[[@B21]\].

Microarray expression data
--------------------------

Publically available gene expression data from high-risk metastatic neuroblastomas, series GSE13136 \[[@B22]\], platform Affymetrix Human Genome U133 Plus 2.0, which were selected by the presence of MNA (GSM328993, GSM328996, GSM329000, GSM329006, GSM329007, GSM329008, GSM329011, GSM329012, GSM329013, GSM329015) or segmental 11q loss (GSM328992, GSM328995, GSM328997, GSM328999, GSM329002, GSM329010, GSM329014, GSM329017) were downloaded from Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>) and normalized in Expression Console v1.1 (3\' Expression Arrays-RMA, Affymetrix).

The Swedish childhood cancer database
-------------------------------------

Clinical data and the *MYCN* copy number status for neuroblastomas diagnosed in Sweden during the 25-year period of 1984--2008 were obtained from the Swedish Childhood Cancer Registry. The clinical criteria for inclusion were the same as for the array study. The limit for MNA was set at \>4 copies of *MYCN* per haploid genome, as determined by FISH and/or SNParray.

Statistical analysis
--------------------

To analyze differences in DNA copy number among the tumor groups, Fisher's exact test was used within the Nexus Copy Number 5.0 analysis program (BioDiscovery, Inc., El Segundo, CA, USA). To search for genes that were differentially expressed among the tumor groups, an empirical Bayes moderated *t*-test was applied using the 'limma' package \[[@B23]\] and p-values were adjusted in accordance with the method of Benjamini and Hochberg \[[@B24]\]. Clinical data were processed using PASW Statistics 18.0 software (SPSS; Chicago, IL, USA). Mean differences in age were examined with the *t*-test for independent samples. Co-variations were analyzed by correlation analysis, and the results were expressed as Pearson correlation coefficients.

Results
=======

Identification of two major unfavorable neuroblastoma groups with different genomic signatures
----------------------------------------------------------------------------------------------

To visualize the results from the complete set of tumors, the percentages of tumors with copy number change were calculated and plotted relative to the position along the chromosomes (Figure [1](#F1){ref-type="fig"}A). All individual profiles are also illustrated (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). Partial or complete gain of one or two copies of the 17q arm was the most common aberration (88% of the tumors), followed by loss of 1p segments (56%), MNA (47%), and loss of 11q (47%; 14 tumors with segmental loss and 2 with loss of one entire chromosome 11) (Figure [1](#F1){ref-type="fig"}A and Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). Subsequently, we examined the frequencies of copy number changes in tumor subgroups that were defined on the basis of the absence or presence of MNA and segmental 11q loss (11q-); hence, the tumors were separated into four subgroups: MNA^not11q-^ (n=14), 11q-^notMNA^ (n=12), MNA and 11q- (n=2), and neither MNA nor 11q- (n=6). The results are shown in Figure [1](#F1){ref-type="fig"}B-D and Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1. Selected profiles from each group are shown in Figure [2](#F2){ref-type="fig"}. Analysis using Fisher's exact test of differences between the MNA^not11q-^ and 11q-^notMNA^ groups (which contained most of the samples, 26/34; 76%) revealed that loci on 1p, 2p, 3p, 5q, 7, 11, 12, 18p, and 20q were differentially altered between the two sets of tumors (Figure [1](#F1){ref-type="fig"}E). These groups also differed in terms of the number of SCAs (mean 5.5 and 12.0, respectively; Table [1](#T1){ref-type="table"}, p\<0.001, Wilcoxon's test), and with regard to an absence of numerical whole chromosomal aberrations, which was the case in 11/14 MNA^not11q-^ tumors, but in only 2/12 11q-^notMNA^ tumors (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). Finally, tumors that showed neither MNA nor 11q- were more heterogeneous in terms of both segmental and whole chromosomal aberrations; two tumors showed aberrations in chromosome number for the majority of chromosomes (ID 131 and ID 242; Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1).

![**Genetic findings in unfavorable neuroblastoma.**The frequency of copy number changes was calculated for all measurement points in the arrays and plotted relative to the position along the chromosome for: (**A**): all tumors, (**B**): MNA^not11q-^tumors, (**C**): 11q-^notMNA^tumors, (**D**): neither MNA nor 11q loss tumors. The number of analyzed tumors is indicated (n). Green bars above the horizontal line indicate the percentage of tumors with copy gains and red bars below the horizontal line indicate the percentage of tumors with copy losses. Data for the X chromosome were normalized to female reference DNA and the respective proportion of boys in panels A-D were: 56%, 43%, 67%, and 67%, respectively (**E**): To search for copy number alterations that differ between the11q-^notMNA^and MNA^not11q-^groups, the frequency percentage *difference*between the two groups are plotted: *Copy number gain difference*(green graph): Values above baseline represent regions in which gains are more numerous among 11q-^not\ MNA^ tumors, and vice versa for values below baseline. *Deletion difference*(red graph): Values above baseline represent regions in which losses are more common among MNA^not11q-^tumors, and vice versa for values below baseline. The regions significantly differentially altered between the groups, identified by using Fisher\'s exact test within Nexus copy-number software, (p\<0.05 and threshold difference in frequency \>25%), are shown below the graph, as indicated by a black arrow.](1471-2407-13-231-1){#F1}

![**Examples of individual neuroblastoma profiles within genetic subgroups.**(**A**) MNA^not11q-^; (**B**) 11q-^notMNA^; (**C**) combined MNA and segmental 11q loss; (**D**) neither MNA nor segmental 11q loss; (**E**) shows an expanded segment of chromosome 12 in panel (D). Amplified genes of particular oncogenic interest are indicated. Each individual clone was assigned a copy number class as follows: *i)*balanced: two alleles (blue dots); *ii)*gained: presence of three (red) or more (pink dots) alleles; or *iii)*deleted: hemizygous deletions (green dots). No homozygous deletions were found in these tumors. Black arrows indicate MNA amplification, 11q loss or other amplifications.](1471-2407-13-231-2){#F2}

Age dependence of genetic subgroups
-----------------------------------

As shown in Table [1](#T1){ref-type="table"} and in Figure [3](#F3){ref-type="fig"}, MNA tumors were diagnosed early in life. In fact, 11 out of the 12 children who were youngest at diagnosis suffered from MNA tumors. If an outlier amongst the MNA group in terms of genetic profile and age (ID126; Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1) is disregarded, only two 11q-^notMNA^ tumors were diagnosed in the same young age range as that of the remaining MNA^not11q-^ tumors (Table [1](#T1){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Statistically, the ages at diagnosis of children with MNA^not11q-^ tumors differed highly significantly from those of children with 11q-^notMNA^ tumors (mean age: 27.4 *vs.* 69.5 months, respectively; p=0.008; median age: 18 *vs.* 58.5 months, respectively; n=14 *vs.* 12).

![**Age at diagnosis in unfavorable neuroblastoma (n=34).**Each tumor in the present study is plotted on a time axis according to age at diagnosis and genetic subgroup. Color symbols indicate the likely site of origin.](1471-2407-13-231-3){#F3}

To test the validity of these findings in a larger sample, we utilized the Swedish Childhood Cancer Registry, which contained clinical information and data on the copy number of *MYCN* in tumors for 240 cases of neuroblastoma that were diagnosed during almost the same time period as the cases in the present study. Among these, 112 were unfavorable cases (100 high risk and 12 intermediate risk who suffered lethal tumor progression). Of the tumors included in the current study, 25 were represented among these 112 cases in the registry, and 11 of the 25 were cases with MNA. Given that 11q status is not registered consistently in the database, we compared the age at diagnosis of children with MNA tumors to those with non-MNA tumors. This analysis revealed highly significant differences both for the present study (MNA *vs.* non-MNA: mean: 29.5 *vs.* 65.6 months; p=0.005; median age: 21 *vs.* 58 months; n=16 *vs.* 18) and for cases of unfavorable neuroblastoma in the registry that were not included in the present study (MNA *vs.* non-MNA: mean age: 29.2 *vs.* 49.1 months; p=0.001; median age: 24 *vs.* 43.5 months; n=43 *vs.* 44). To determine whether the MNA cases included in our study might be biased towards a younger age range, we compared their ages at diagnosis to those of the other MNA cases in the registry and found no statistical difference (mean: 29.5 *vs.* 29.2 months; median: 21 *vs.* 24 months; p=0.968; n=16 *vs.* 43). There was also no statistically significant difference in the distribution of ages at diagnosis for non-MNA tumors (mean: 65.6 *vs.* 49.1 months; median: 58 *vs.* 43.5 months; p=0.098; n=18 *vs.* 44).

When the findings were merged, we were able to conclude that, among Swedish children who were diagnosed with unfavorable neuroblastoma during this time period, MNA tumors were almost four-fold more common than non-MNA tumors when diagnosis was made before two years of age (31 *vs.* 8), whereas this relationship was reversed in children who were diagnosed after 3.5 years of age (10 *vs.* 35; Figure [4](#F4){ref-type="fig"}).

![***MYCN*amplification status and age at diagnosis of Swedish patients with unfavorable neuroblastoma (n=121).**Present cases, representing the period 1986--2010, have been merged with all other cases of unfavorable neuroblastoma found in the Swedish Childhood Cancer Registry during the period 1984--2008. Data is presented in 6-month age intervals. Unfavorable criteria were: lethal tumor progression, *MYCN* amplification, INRGSS Stage M and \>18 months of age at diagnosis, and INRGSS Stage L2 \>12 years of age at diagnosis.](1471-2407-13-231-4){#F4}

In view of the high number of SCAs that were found in tumors with segmental 11q deletion, we investigated the possibility of an age-dependence for the number of SCAs within this tumor subgroup and found a positive correlation with age at diagnosis (Pearson correlation 0.606; p=0.037). When merging the four genetic groups the age dependence of SCA numbers was even more evident with a p-value of 0.001 (Pearson correlation 0.547; Figure [5](#F5){ref-type="fig"}).

![**Age dependence of segmental chromosomal aberrations in unfavorable neuroblastoma (n=34).**Data are separated by genetic subtype, as indicated. X-axis: age at diagnosis (years). Y-axis: number of segmental chromosomal aberrations (SCA; amplicons not included).](1471-2407-13-231-5){#F5}

High copy number amplicons
--------------------------

In total, 17 tumors displayed amplified regions. The number of these amplified regions per tumor varied from one to seven, and their sizes ranged from 0.15 to 6.8 Mb. Of the 16 tumors with MNA, either the *MYCN*-containing amplicon was the only amplification event or it was accompanied by multiple amplified loci within 2p, and in one case by two amplified loci on chromosome 3q. The regions of amplification, their frequencies, and the genes encompassed are listed in Table [2](#T2){ref-type="table"}. In one tumor with MNA and its associated cell line \[[@B15]\], a few novel amplicons were found, which encompassed genes such as *GDF7*, *FSHR*, *PRKCE*, and *TMEM18* (Additional file [2](#S2){ref-type="supplementary-material"}: Figure S2). Overall, 20% of the amplified loci did not encompass any gene (Table [2](#T2){ref-type="table"}). One unusual case (ID 208) displayed multiple amplicons but not MNA. Genes of particular oncogenic interest within these loci were *CCND1*, *FGF4*, *FGF19*, *IGHMBP2, MYEOV*, and *ORAOV1* on 11q13.2-q13.3 and *CDK4*, *MDM2*, and *KSR2* on 12q13.3-q15 (Figure [2](#F2){ref-type="fig"}D-E and Table [2](#T2){ref-type="table"}).

###### 

**Regions of amplification in unfavorable neuroblastoma** (n=17)

    **Chr Region (Mb)**     **Cyto-band**   **Length(Mb)**   **Genes**                                                                                        **Gene Symbols**                                                                                            **Group**       **No of tumors**
  ------------------------ --------------- ---------------- ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------
     chr:2:0.366-0.793          p25.3           0.427            1                                                                                                *TMEM18*                                                                                                   NMA                 1
     chr:2:2.304-6.219       p25.3-p25.2        3.915           12                                                   *ADI1, ALLC, COLEC11, LOC150622, LOC400940, LOC730811, MYT1L, RNASEH1, RPS7, SOX11, TSSC1, TTC15*                                                       NMA                 1
     chr:2:3.605-4.280          p25.3           0.675            3                                                                                         *ALLC, COLEC11, RPS7*                                                                                             NMA                 1
     chr:2:5.708-7.439       p25.2-p25.1        1.731            6                                                                          *CMPK2, LOC150622, LOC400940, RNF144A, RSAD2, SOX11*                                                                             NMA                 1
     chr:2:6.372-6.855          p25.2           0.483            0                                                                                                                                                                                                           NMA                 1
    chr:2:10.413-11.244         p25.1           0.831           10                                                         *ATP6V1C2, C2orf50, HPCAL1, KCNF1, NOL10,****ODC1****, PDIA6, PQLC3, ROCK2, SNORA80B*                                                             NMA                 2
    chr:2:11.622-11.878         p25.1           0.256            3                                                                                         *GREB1, LPIN1, NTSR2*                                                                                             NMA                 1
    chr:2:13.097-13.580         p24.3           0.483            0                                                                                                                                                                                                           NMA                 1
    chr:2:14.219-14.292         p24.3           0.073            0                                                                                                                                                                                                           NMA                 2
    chr:2:15.895-16.095         p24.3           0.200            2                                                                                          ***MYCN****, MYCNOS*                                                                                             NMA                 16
    chr:2:16.675-16.705         p24.3           0.030            1                                                                                                *FAM49A*                                                                                                   NMA                 6
    chr:2:16.846-17.106      p24.3-p24.2        0.260            0                                                                                                                                                                                                           NMA                 6
    chr:2:18.197-18.423         p24.2           0.227            0                                                                                                                                                                                                           NMA                 3
    chr:2:20.546-21.012         p24.1           0.466            3                                                                                        *C2orf43, GDF7, HS1BP3*                                                                                            NMA                 1
    chr:2:22.493-25.674      p24.1-p23.3        3.181           21                  *ADCY3, ATAD2B, C2orf44, C2orf79, C2orf84, CENPO, DNAJC27, DNMT3A, DTNB, EFR3B, FKBP1B, ITSN2, KLHL29, LOC375190, MFSD2B, NCOA1, PFN4, POMC, SF3B14, TP53I3, UBXN2A*                     NMA                 1
    chr:2:26.853-27.169         p23.3           0.316            9                                                              *AGBL5, C2orf18, CENPA, DPYSL5, EMILIN1, KHK, LOC100128731, MAPRE3, TMEM214*                                                                 NMA                 2
    chr:2:28.022-28.430         p23.2           0.408            1                                                                                                 *BRE*                                                                                                     NMA                 2
    chr:2:29.071-30.833      p23.2-p23.1        1.762            8                                                                    ***ALK****, C2orf71, CAPN13, CLIP4, FAM179A, LBH, LCLAT1, YPEL5*                                                                       NMA                 2
    chr:2:38.841-39.010         p22.1           0.168            4                                                                                  *DHX57, GEMIN6, LOC100271715, MORN2*                                                                                     NMA                 1
    chr:2:45.742-46.467          p21            0.725            2                                                                                             *EPAS1, PRKCE*                                                                                                NMA                 1
    chr:2:47.379-47.698       p21-p16.3         0.319            3                                                                                         *EPCAM, KCNK12, MSH2*                                                                                             NMA                 1
    chr:2:48.848-49.512         p16.3           0.664            1                                                                                                 *FSHR*                                                                                                    NMA                 1
   chr:3:170.768-172.093        q26.2           1.325           18                       *ARPM1, CLDN11, EIF5A2, GPR160, LOC100128164, LRRC31, LRRC34, LRRIQ4, MECOM, MYNN, PHC3,****PRKCI****, RPL22L1, SAMD7, SEC62,****SKIL****, SLC7A14, TERC*                           NMA                 1
   chr:3:173.047-173.459       q26.31           0.411            2                                                                                           *FNDC3B, TMEM212*                                                                                               NMA                 1
    chr:11:68.463-69.308     q13.2-q13.3        0.845            9                                                            ***CCND1****, FGF19,****FGF4****, IGHMBP2, MRGPRD, MRGPRF, MYEOV, ORAOV1, TPCN2*                                                        Not NMA, not 11q-          1
    chr:12:56.182-57.066     q13.3-q14.1        0.884           23       *AGAP2, AVIL, B4GALNT1,****CDK4****, CTDSP2, CYP27B1, DCTN2, DDIT3, DTX3, FAM119B, GEFT, KIF5A, LOC100130776, MARCH9, MARS, MBD6, METTL1, OS9, PIP4K2C, SLC26A10, TSFM, TSPAN31, XRCC6BP1*   Not NMA, not 11q-          1
    chr:12:67.060-68.692         q15            1.632           13                                                *BEST3, CCT2, CPM, CPSF6, FRS2, LRRC10, LYZ,****MDM2****, NUP107, RAB3IP,****RAP1B****, SLC35E3, YEATS4*                                            Not NMA, not 11q-          1
    chr:12:71.578-73.413        q21.1           1.835            1                                                                                              *LOC552889*                                                                                           Not NMA, not 11q-          1
    chr:12:83.287-83.563       q21.31           0.276            0                                                                                                                                                                                                    Not NMA, not 11q-          1
   chr:12:116.476-116.802   q24.22-q24.23       0.326            1                                                                                                 *KSR2*                                                                                             Not NMA, not 11q-          1

Regions that involved at least two neighboring clones, with copy number count \>3 and normalized fluorescence ratio \>2 are shown. For amplicons with regions shared between tumors, the minimal overlapping region is shown. Genes of particular oncogenic interest in neuroblastoma are indicated in bold.

Differentially expressed genes within aberrant regions of MNA and 11q-deleted tumors
------------------------------------------------------------------------------------

Given that MNA and 11q- neuroblastomas present with divergent genomic signatures, we sought differences in gene expression profiles within the regions that differed most consistently between these two groups (1p, 2p, and chromosomes 7 and 11). For this purpose, we compared publicly available gene expression data for high-risk neuroblastomas with recorded MNA and 11q status (see Methods). Among the MNA tumors (n=10), five tumor suppressor genes (among other genes) were underexpressed within the distal 1p: *CAMTA1*, *KIF1B*, *PRDM2*, *FABP3*, and *CDKN2C*; whereas *MYCNOS* and *MYCN* were the two top differentially upregulated genes on 2p. Several constituents of the extracellular matrix or membrane proteins involved in cell adhesion, motility or proliferation that map to chromosome 7, namely *PTN*, *CNTNAP2*, *ELN*, *HSPB1*, *SEMA3E*, and *COL1A2*, were upregulated in the 11q-deleted group (n=8). In the same group of tumors, *CD44* was the top upregulated gene on 11p. Interestingly, on 11q, several tumor suppressor genes and genes encoding DNA-binding proteins involved in DNA repair and negative regulation of transcription were downregulated in the 11q-deleted tumors: *C11orf30*, *RSF1*, *CREBZF*, *FAT3*, *MRE11A*, *ATM*, *CADM1*, *MLL*, *H2AFX*, *TBRG1*, and *CHK1*.

Discussion
==========

In this report, we describe the DNA copy number profiles of a consecutive series of neuroblastomas that were selected on the basis of unfavorable characteristics. The findings revealed considerable genetic heterogeneity within this clinically troublesome group, which was particularly evident when comparing tumors with MNA to those with segmental 11q deletions. With few exceptions, MNA and segmental 11q loss were mutually exclusive and defined two genetic subgroups of equal size that comprised more than three-quarters of the total samples. Such genetic dichotomy of advanced neuroblastoma has been well described previously \[[@B2],[@B7],[@B8],[@B11],[@B15]\] and both MNA and segmental 11q loss are included in the current INRG algorithm for pretreatment stratification of risk \[[@B10]\]. Less predictably, we also observed a clear clinical difference between these two genetic subgroups in relation to age: MNA tumors affected the youngest children of the series. It is surprising that this age dependence with respect to the tumor genetics of neuroblastoma has not received much scientific attention previously, although mentioned in several previous studies \[[@B9],[@B11],[@B15],[@B25]\]. In view of the relatively moderate size of the present tumor series, it was important that we were able to confirm a generally low age at diagnosis for children with MNA tumors using independent data from the Swedish Childhood Cancer Registry; these data argued clearly against a bias in the present material. We conclude from the present findings that unfavorable neuroblastomas are predominantly of the MNA type when diagnosed under the age of 2 years, whereas tumors with loss of 11q and other genetic variants predominate after 3.5 years of age.

As the Swedish Childhood Cancer Registry, due to lack of records, could not be used to verify the older age at diagnosis for children with 11q-deleted tumors we searched the literature for this information: Spitz et al. \[[@B9]\] reported on segmental 11q deletions from a cohort of 611 neuroblastomas, found in 159 tumors. The median age at diagnosis of these 11q-deleted tumors was 3--5 years, constituting 59 percent of the tumors of this age range. Michels et al. \[[@B11]\] reported 48 and 28 months as median ages at diagnosis for ten 11q-deleted and 22 MNA tumors, respectively. In a meta study by Vandesompele et al. \[[@B25]\] poor risk neuroblastomas were separated into two genetic "clusters": The median age of 45 children belonging to the 11q deletion "cluster" was 41 months, although notably only 30 of the tumors were actually 11q deleted. The corresponding figures for 74 children belonging to the MNA "cluster" was 26.9 months median age with actual MNA seen in 51 tumors. Finally, Carén et al. \[[@B15]\] reported a median age of 42 months for 21 children with 11q-deleted tumors (four of which were common with our study) compared to 21 months for 37 children with MNA tumors (seven in common with our study). Together, these data consistently support an age difference between the two groups, although a certain bias towards older ages for 11q-deleted tumors in the present study is observed (58.5 months median age).

Another difference that was observed between MNA and 11q-deleted tumors was the higher number of SCAs in the later group of tumors and a dependence of their prevalence on age, both of which imply a chromosomal instability phenotype, as suggested previously by Carén et al. \[[@B15]\]. Future analyses using larger sample sizes, including multiple tumor specimens (synchronous and metachronous), might be helpful in confirming such chromosomal instability. Also, deep sequencing might shed additional light on differences in genomic integrity at the DNA level among subsets of neuroblastoma. A recent report \[[@B26]\], based on whole-genome sequencing of 87 neuroblastomas of all stages, showed that the frequency of somatic amino-acid-changing mutations strongly correlated to tumor stage, survival, and age at diagnosis. However, no difference in frequency of such mutations was detected when comparing MNA tumors to high-stage non-MNA tumors. Hence, this aformentioned study reported a general age dependence of amino-acid-changing mutations in neuroblastoma, albeit the specific issue of DNA instability in tumors with deleted 11q, as compared to MNA tumors, was not addressed.

On the basis of the profile subtypes that were observed in the presently relatively limited series of tumors, and in view of previous data by others, we speculate on the existence of four genetic routes for the genesis of aggressive neuroblastoma:

The MNA route
-------------

MNA neuroblastomas seem to fit into a model of rapid tumor evolution that involves only a few genetic events, which transform the progenitor cells into highly proliferative and primary metastatic tumor cells in a straightforward fashion. The likelihood of such few events to take place would, logically, be more proportional to the pool of cells of origin than for tumors requiring a larger sequence of genetic hits (e.g. 11q deleted tumors), hence explaining the early in life appearance of MNA tumors.

The 11q route
-------------

It appears that the pathogenesis of tumors with segmental 11q loss accords with the traditional genetic model for adult cancer, which predicts a micro-evolutionary process of cancer development, with successive genetic hits affecting key cellular functions \[[@B27]\]. Acquisition of chromosomal instability might be fundamental in this process. Our analysis of differential gene expression in 11q-deleted tumors *vs.* MNA neuroblastomas pinpointed some candidate tumor suppressor/DNA repair genes within the region of 11q that is deleted, such as *ATM*, *MLL*, *H2AFX*, and *CHK1*. Recently, the importance of aberrant gene expression within this region was underscored by the finding that decreased expression of genes within the region of interest at 11q was observed only in those 11q-deleted tumors with an aggressive clinical phenotype \[[@B28]\]. It is noteworthy, in this context, that a subgroup of 11q-deleted tumors with more favorable clinical characteristics has been described \[[@B28],[@B29]\]. Apart from not showing a disproportionate downregulation of the expression of genes of the deleted region, such tumors were also reported to differ from unfavourable 11q-deleted tumors regarding microRNA expression profiles \[[@B29]\] and by having less SCAs \[[@B28]\]. It is therefore possible that the here suggested 11q route is not an important element in the pathogenesis of less aggressive tumors with 11q deletions. Evidently, our statistics on the present 11q-^notMNA^ tumors represents the unfavorable type of 11q-deleted neuroblastoma since there was only one survivor in this group. It is noticeable in this context that our inclusion criteria would discriminate against tumors of the more favorable subtype.

The tumor progression route
---------------------------

A third possibility in the evolution of aggressive neuroblastoma is progression from lower-risk tumors \[[@B13]\]. Although progression from a low-risk lesion to an aggressive tumor is considered in general to be a rare event, we think that three of the nonMNA/non11q deleted tumors in the present study might have evolved in this way. Two tumors showed genetic similarity to low-risk tumors in that they showed whole chromosome aberrations for more than half of the chromosomes and only few segmental gains or losses. It appears particularly likely that a third tumor (ID 226) was derived from a lower-risk tumor: on diagnosis at 7.5 years of age, it was revealed that a chest X-ray taken 6 years earlier already then showed the primary tumor. Genetically, the tumor had much in common with 11q deleted tumors, but 11q was intact.

Alternative amplicon driven routes
----------------------------------

An unusual genetic variant of the present study was a tumor with multiple amplicons on 11q and 12q. There are other examples in the literature of neuroblastoma cell lines and tumors with very similar amplified regions at 11q13 \[[@B11],[@B25]\] or 12q13--q15 \[[@B11],[@B21],[@B30]\], respectively, and in two tumors synchronous amplification on both chromosomes have been reported \[[@B11],[@B31],[@B32]\], as in the present case. *CCND1*, *IGHMBP2*, *ORAOV1*, *FGF4* on chromosome 11q13, and *CDK4* and *MDM2* on 12q13-15 are interesting oncogenes in this context. Generally, neuroblastomas with 11q13 amplicons were reported to be clinically aggressive and associated with an older age at diagnosis compared to children with MNA tumors of the present study. However, those 11q13 amplified neuroblastomas which also displayed MNA were diagnosed at earlier ages \[[@B11]\]. Clinical information on 12q amplified neuroblastoma is sparse in the literature but indicates advanced disease \[[@B30],[@B33],[@B34]\]. MNA may occur also in 12q amplified neuroblastoma \[[@B21],[@B30],[@B31]\]. Amplicons of other chromosomal regions are described in single cases of poor outcome neuroblastoma, involving 16q.21, 4q.33, 6p12-21 \[[@B25]\], 5q33.3 \[[@B11]\], and the *MYC* containing 8q24 region \[[@B26]\]. Hence, with the support of these previously published data, it seems that our case harboring chromosome 11 and 12 amplifications is not totally unique and implies that such and other non-*MYCN* amplifications may underlie a minor subset of aggressive neuroblastomas.

Conclusions
===========

On the basis of these categories, we suggest the following metaphor for the genesis of unfavorable neuroblastoma: MNA, segmental deletion of 11q, and low-risk precursor lesions provide an elevator, a staircase, and a first step of a staircase, respectively, towards unfavorable neuroblastoma. This metaphor builds on the notion that the first steps in tumor development take place during a common early developmental phase when the immature cells that are the source of neuroblastoma are still present in the sympathetic nervous system, whereas subsequent tumorigenic events differ in malignant effect between the genetic routes. Our speculations on main routes for the pathogenesis of unfavourable neuroblastoma are summarized in Figure [6](#F6){ref-type="fig"}, showing the four mentioned routes and adding also adolescent neuroblastoma as a separate, but still obscure, route. The present delineation of genetic subsets of unfavorable neuroblastoma might have therapeutic implications. It would seem that MNA tumors are more proliferative, which calls for a dose-intensive treatment, and the relatively "clean" genetics of MNA neuroblastomas would appear to make them suitable for tailored treatments that target the functions of MYCN, e.g. apoptosis \[[@B35]\]. Novel therapeutic strategies specifically for 11q-deleted neuroblastoma are urgently needed, and the identification of novel subsets of neuroblastomas with non-*MYCN* amplifications may also have therapeutic consequences, but these will have to await more conclusive information on the genetic and clinical homogeneity of such tumors. Finally, the possibility of a transition from low- to high-risk disease in some cases may have implications for the monitoring of low-risk rest tumors.

![**A proposed model for the age dependence of unfavorable neuroblastoma.**The model builds on the assumption of an early common cellular origin of all neuroblastomas. Depending on genetic subtype the respective tumorigenic hits differ in type, number and degree of malignant effect - most evident when comparing MNA and 11q- tumors. As tumors with alternative amplifications, putative low-to-high-risk progression, and adolescent presentation are poorly represented in the present study and in the literature these routes for tumor development are largely speculative, indicated by question marks. *Abbreviation*: NB: neuroblastoma; *Symbols*: Arrows: tumorigenic hits; Darkness of arrow: degree of malignant transformation; Arrow width/size of symbol for clinical disease: relative frequency of tumor subtype; Solid curved blue line: low-risk neuroblastoma development.](1471-2407-13-231-6){#F6}
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###### Additional file 1: Figure S1

Schematic representation of genetic profiles for neuroblastoma samples included in the study (n=34). Deleted and gained regions are represented by red and green bars, respectively. Cases are arranged according to genetic subgroup.
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###### Additional file 2: Figure S2

Novel amplicons in association with MNA on 2p: 32K whole-genome array data are shown from: (A) the primary tumor of case ID55; (B) cell line U2715, which was established from this tumor.
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